Andrew D Norden1, Jan Drappatz, Patrick Y Wen. 1. Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. anorden@partners.org
Abstract
PURPOSE OF REVIEW: Antiangiogenic drugs are increasingly used in malignant glioma therapy. This article reviews the rationale for targeting angiogenesis in malignant gliomas, summarizes relevant clinical trial results, and discusses promising avenues of investigation in antiangiogenic therapy. RECENT FINDINGS: Combination therapy with bevacizumab, the humanized monoclonal antibody against vascular endothelial growth factor, and irinotecan has emerged as the treatment of choice for recurrent malignant gliomas, prolonging progression-free survival markedly in comparison with historical controls. Several small molecule tyrosine kinase inhibitors of the vascular endothelial growth factor receptor are under investigation and show promise as well. SUMMARY: Antiangiogenic treatments are effective and well tolerated options for recurrent malignant glioma. Future studies will determine whether these drugs have a role in first line therapy. Studies are in progress to elucidate mechanisms of resistance and suggest approaches to further improve survival in patients with these challenging tumors.
PURPOSE OF REVIEW: Antiangiogenic drugs are increasingly used in malignant glioma therapy. This article reviews the rationale for targeting angiogenesis in malignant gliomas, summarizes relevant clinical trial results, and discusses promising avenues of investigation in antiangiogenic therapy. RECENT FINDINGS: Combination therapy with bevacizumab, the humanized monoclonal antibody against vascular endothelial growth factor, and irinotecan has emerged as the treatment of choice for recurrent malignant gliomas, prolonging progression-free survival markedly in comparison with historical controls. Several small molecule tyrosine kinase inhibitors of the vascular endothelial growth factor receptor are under investigation and show promise as well. SUMMARY: Antiangiogenic treatments are effective and well tolerated options for recurrent malignant glioma. Future studies will determine whether these drugs have a role in first line therapy. Studies are in progress to elucidate mechanisms of resistance and suggest approaches to further improve survival in patients with these challenging tumors.
Authors: Leon D Ortiz; Luis V Syro; Bernd W Scheithauer; Ayca Ersen; Humberto Uribe; Camilo E Fadul; Fabio Rotondo; Eva Horvath; Kalman Kovacs Journal: Pituitary Date: 2012-09 Impact factor: 4.107
Authors: Bob Hamans; Anna Catharina Navis; Alan Wright; Pieter Wesseling; Arend Heerschap; William Leenders Journal: Neuro Oncol Date: 2013-10-24 Impact factor: 12.300
Authors: B R Achyut; Adarsh Shankar; A S M Iskander; Roxan Ara; Robert A Knight; Alfonso G Scicli; Ali S Arbab Journal: Cancer Biol Ther Date: 2016-01-21 Impact factor: 4.742
Authors: Meser M Ali; Branislava Janic; Abbas Babajani-Feremi; Nadimpalli R S Varma; A S M Iskander; John Anagli; Ali S Arbab Journal: PLoS One Date: 2010-01-15 Impact factor: 3.240
Authors: Yi-Hong Zhou; Yuanjie Hu; Debra Mayes; Eric Siegel; Jae G Kim; Marlon S Mathews; Nelson Hsu; Daniel Eskander; Ong Yu; Bruce J Tromberg; Mark E Linskey Journal: J Neurooncol Date: 2009-07-19 Impact factor: 4.130